Себозол

Quick links

Choose a section

Quick links to important sections

Advertisements

Себозол

Advertisements
Advertisements

Overview of Себозол

Quick Facts

Property Description
Active Ingredient Ketoconazole (INN)
Form Topical (Shampoo, Cream, Gel, Foam)
Pharmacological Class Azole Antifungal / Imidazole Derivative
Common Use Fighting fungal and yeast infections
Origin Synthetic Compound

What Type of Medicine is Sebozol and What is Its Active Ingredient?

Sebozol is a synthetic antifungal agent, or antimycotic, containing the active substance Ketoconazole. It is classified within the Azole antifungal pharmacological class, confirming its design as a chemical entity engineered to halt the growth of fungi and yeasts.

The compound Ketoconazole is a synthetic organic molecule and an Imidazole derivative. This identity establishes Sebozol as a targeted agent primarily for superficial fungal infections. Pharmacological data indicates its capability to suppress the growth of various pathogenic fungi. This means the medicine is scientifically recognized to stop the infection-causing organisms from multiplying.


What Forms Does Sebozol Come In and What is Its General Purpose?

Sebozol is predominantly presented in several topical dosage forms, including shampoo, cream, gel, and foam, for a direct route of administration. While the active ingredient can also be formulated into oral tablets, the Sebozol product line utilizes these topical preparations to facilitate localized treatment where the fungal infection is present.

The overall purpose of Sebozol is to combat and eliminate fungal infections by attacking the fundamental structural integrity of the organism. By inhibiting the fungal cell's ability to produce ergosterol, a sterol essential for its membrane, the drug functions as a broad-spectrum agent. This action ensures the medicine actively works to dismantle the cells of the infection. The general benefit is the effective control of fungal overgrowth, such as those found on the scalp or skin.

Advertisements

What side effects are possible with Себозол?

Possible Side Effects and Safety Information

The safety profile of Себозол (Ketoconazole) topical formulations is primarily characterized by local adverse reactions, given the minimal systemic absorption of the active substance through the skin or scalp.

Common Adverse Reactions (Affecting 1% to 10% of users)

Adverse reactions most frequently reported occur at the application site and are typically mild, including:

  • Skin burning sensation.
  • Application site pruritus (itching) or erythema (redness).
  • Dry skin.

Uncommon and Rare Adverse Reactions

Less frequently reported reactions, generally affecting less than 1% of users, may involve other organ classes and include:

System-Organ Class Uncommon (ge 0.1% to <1%) Rare (<0.1% or Post-Marketing)
Skin Disorders Contact dermatitis, skin rash, abnormal hair texture, hair loss (alopecia), bullous eruption. Urticaria (hives), skin exfoliation.
Immune System Hypersensitivity reactions. Severe hypersensitivity, including angioedema (swelling of the face, lips, or tongue).
Nervous System Headaches. Dysgeusia (taste impairment).
Other Increased lacrimation (tearing). Eye irritation.

Safety Restrictions and Contraindications

The product is contraindicated in individuals with known hypersensitivity or allergy to ketoconazole or any of the excipients contained in the specific formulation. If a severe reaction suggesting sensitivity or chemical irritation, such as worsening redness, blistering, or signs of a serious allergic reaction, occurs, use must be discontinued.

Topical formulations are for external use only. Care must be taken to avoid contact with the eyes; if contact occurs, rinse thoroughly with water. Pregnant and breastfeeding individuals should use the medication only if the potential benefit justifies the potential risk, as per regulatory advisories, although systemic plasma concentrations following topical use are typically below detectable limits.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for topical ketoconazole overdose distinguishes between local overuse and accidental ingestion. Due to the product's negligible systemic absorption, severe, life-threatening, or systemic outcomes (such as those associated with the oral formulation) are not documented as expected risks from the topical product.

Scenario Manifestation and Required Action
Excessive Topical Application Manifestations: Overdose resulting from excessive topical application is officially documented to produce localized skin reactions, including erythema (redness), oedema (swelling), and a burning sensation. Action: These transient local symptoms will disappear upon discontinuation of the treatment and do not require urgent medical attention.
Accidental Ingestion Manifestations: Accidental ingestion represents the key concern for systemic exposure. Action: In this event, regulatory authorities mandate that the user contact a Poison Control Center or a health care provider immediately for guidance.

The immediate help-seeking requirement is strictly tied to accidental ingestion. For this scenario, the required management procedure is the provision of supportive and symptomatic measures, as regulatory documents state that no specific antidote is known for this medication. For the localized skin reactions caused by excessive topical application, the mandated action is simply to stop the application.

Advertisements

Therapeutic Uses of Себозол

What Себозол Treats: Main Uses and Benefits

The active ingredient in Sebozol is generally used to manage a number of skin and scalp conditions associated with fungal and yeast overgrowth. This supportive use is relevant for conditions presenting with symptoms of localized discomfort and inflammation, including Seborrheic Dermatitis, various Tinea infections (such as athlete's foot and ringworm), and Pityriasis Versicolor.

This medication is commonly used during phases when symptoms become more noticeable, particularly the clusters of intense itching, redness, and scaling/flaking that interfere with daily comfort. This supportive use helps ease the overall symptom burden. The therapeutic use is focused on addressing the fungal factors, which supports management of the visible manifestations.


Quick Fact: Support for Fungal Symptom Management
Primary Goal Symptomatic management of fungal/yeast factors
Symptom Focus Itching (pruritus), scaling, and inflammatory redness (erythema)
Key Scenarios Chronic flaking (dandruff) and localized skin patches (tinea)
Patient Benefit Supports day-to-day comfort during symptomatic periods

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Себозол — Official Regulatory Information

The eligibility profile for Себозол (Ketoconazole 2% Topical Shampoo) is defined by official government regulatory documents, focusing on absolute exclusions and populations requiring special consideration.


Category Official Regulatory Statement
Populations for whom use is contraindicated Persons with known hypersensitivity or allergy to ketoconazole or any of the formulation's excipients.
Populations for whom use is not established Children under 12 years of age, as safety and efficacy have not been established in this age group.
Pregnancy and Lactation Eligibility Conditional use. Caution should be exercised. Use is generally advised only if the potential benefit justifies the potential risk to the fetus or nursing child.
Eligibility-Related Restrictions Use requires caution on broken or inflamed skin. Patients transitioning from prolonged topical corticosteroid use should gradually withdraw the steroid over several weeks while beginning the shampoo to prevent a potential rebound effect.

Connection to the overall eligibility profile:

Regulatory documents establish the primary exclusion based on a documented history of allergy to the ingredients, which is an absolute contraindication. Use is further limited in pediatric patients due to a lack of established safety data. Special caution and a risk-benefit assessment are required for use during pregnancy and breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for topical ketoconazole (Себозол) is strictly governed by its official regulatory status, which confirms minimal systemic absorption.


Systemic Drug Interactions

Regulatory documentation confirms that systemic drug-drug interactions are not expected with the topical formulation. Studies show that plasma concentrations of the active substance are often undetectable following application to the skin or scalp. This negligible systemic exposure dictates that the product does not pose a clinically significant risk for interactions seen with the oral formulation, such as those mediated by the CYP enzyme system or drug transporters. Therefore, official labels carry no mandatory restrictions regarding the co-administration of topical ketoconazole with systemic prescription or over-the-counter medicines.


Local Administration Restrictions

The only documented interaction pattern is a local pharmacodynamic effect involving topical corticosteroids. Official regulatory labeling cites that co-application requires procedural management to prevent a potential rebound effect, where the skin condition may worsen after the corticosteroid is discontinued. The mandatory official requirement is the gradual withdrawal of the topical corticosteroid, typically phased over a two-to-three-week period, while the antifungal agent remains in use. This constraint is specific to local administration timing.


Interactions with Food or Supplements

Official government documents do not cite any interactions between the topical formulation of ketoconazole and food, alcohol, or herbal supplements.

Advertisements

Mechanism of Action

How Себозол Works

Себозол's mechanism of action involves a targeted biochemical attack on the fungal cell, resulting in the suppression of fungal cell function and growth.


Inhibiting the Fungal Ergosterol Biosynthesis Pathway

The active ingredient, Ketoconazole, initiates its action by binding to and inhibiting a specific fungal enzyme called Cytochrome P450 14alpha-demethylase ( CYP51A1). This enzyme catalyzes a critical step in the pathway that synthesizes ergosterol, the primary sterol of the fungal cell membrane. The consequence of this inhibition is a marked reduction in ergosterol production and the buildup of toxic metabolic precursors inside the organism .


Disrupting Cell Membrane Integrity and Structure

The lack of functional ergosterol and the presence of toxic sterol byproducts critically destabilize the fungal cell membrane, leading to increased permeability and structural failure. This physiological cascade reduces the organism's capacity to maintain osmotic balance and compromises its ability to grow, replicate, or repair its structure. This action is mechanistically classified as fungistatic (arresting growth) but can result in a fungicidal effect (inducing cell death) at higher local concentrations, depending on the fungal species.

Advertisements

Dosage and Administration Information

The usage of this medication, which contains the active ingredient Ketoconazole, is standardized according to established protocols detailing its localized application. Topical formulations, which include the 2% shampoo, cream, gel, and foam, are intended exclusively for cutaneous administration. The specific application frequency and duration depend upon the formulation and the target condition.

For managing conditions like Seborrheic Dermatitis, the 2% shampoo is typically applied twice weekly for an initial treatment period of two to four weeks. Conversely, the cream formulation used for Tinea infections, such as Tinea Corporis, is generally applied once daily, with treatment courses ranging from two weeks up to six weeks for infections like Tinea Pedis. Treatment for Tinea Versicolor is often managed with a single application or a course of up to five days. For prophylactic use against Seborrheic Dermatitis recurrence, the shampoo is used intermittently, such as once every one to two weeks.

Procedurally, proper administration requires specific steps to ensure contact time. When using the shampoo, the product must be applied, lathered, and left on the affected scalp or skin for three to five minutes before being rinsed thoroughly. Creams and gels require gentle rubbing into the affected area and the surrounding skin margin. Furthermore, an important high-level instruction specifies that patients transitioning from long-term use of topical corticosteroids should undergo a gradual withdrawal of the steroid over two to three weeks upon starting this antifungal treatment.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Себозол (Topical Ketoconazole)


Evidence for Use in Seborrheic Dermatitis and Dandruff

The primary research for managing seborrheic dermatitis and associated flaking consists of short-term Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. Research examined this medicine against inactive substances (placebo vehicle) and other treatments. Studies focused on clinical outcomes, where researchers measured the degree of clearance or improvement in key symptoms such as scaling, redness, and itching. Furthermore, mycological outcomes involved tracking the fungal status of the affected areas.

Research exploring short-term symptom changes reported that specific measured patterns in outcomes differed between groups using the active ingredient and those using the inactive vehicle. Studies monitored how symptoms evolved in the observed populations, and research reported the frequency of measured clinical status changes in the groups using the active substance. Long-term effects are not fully established; evidence is limited for understanding management strategies needed after the initial symptomatic period ends.


Evidence for Use in Tinea Versicolor

Evidence for pityriasis versicolor comes primarily from short-term clinical trials. The main goal of research examined in this context was to evaluate the measurement of overall status, which involved tracking both the change in visible lesions and mycological clearance, meaning a negative result for the presence of the fungus. Research highlights changes measured during the study period, reporting the frequency of specific measurements achieved for both clinical and mycological status.

Scientific reviews indicated that certainty remains low in some of the comparative evidence, and evidence quality varies across studies due to heterogeneity in methods. The follow-up durations were limited, meaning that long-term outcomes are not fully established, particularly regarding recurrence risk.


What is Still Uncertain About the Research for Себозол

Evidence highlights what is known—and what is still uncertain—about this medicine. A primary limitation is that long-term effects are not fully established, with most controlled studies focusing only on short-term or intermediate outcomes. Additionally, evidence quality varies across studies, especially for tinea infections, where published research is often older and involves small populations. Comparative evidence is lacking to definitively differentiate this medicine from all other treatment options for fungal infections.

Key Studies & References

  1. Tinea Corporis (StatPearls/NCBI Bookshelf - Clinical Treatment Guideline)
  2. Label: KETOCONAZOLE cream 2% (DailyMed - Regulatory and Safety Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Себозол (FAQ)


Q: What types of scalp conditions is Себозол generally used for?

The active ingredient in this medicine is officially indicated for the topical treatment of conditions such as dandruff and seborrheic dermatitis, as well as various tinea infections like ringworm of the body (tinea corporis), athlete's foot (tinea pedis), and tinea versicolor.

Q: Does Себозол only treat the symptoms of dandruff or the underlying cause?

Regulatory documents describe the medicine's action, which is thought to target the underlying cause by impairing the synthesis of ergosterol, a component vital for fungal cell membranes. This action is thought to lead to a reduction in the population of yeast species associated with the condition.

Q: How quickly do people typically begin to see results after starting Себозол treatment?

Official product information notes that for some formulations, such as the cream, clinical improvement may be seen fairly soon after treatment is started. However, it is important to follow the recommended treatment duration.

Q: What is the expected timeframe for symptoms like flaking and itching to start clearing up?

While clinical trials report that improvement may begin fairly soon after starting the product, regulatory instructions specify the full duration of treatment (e.g., two to four weeks for certain conditions).

Q: Can symptoms like itching and scaling return after stopping the recommended use of Себозол?

Official guidance suggests that completing the full recommended treatment period may help reduce the possibility of recurrence of the fungal infection. Some treatment plans include using the product intermittently for maintenance after the initial period ends.

Q: Are there any official studies that describe the long-term effectiveness of Себозол's active ingredient?

Official research summaries indicate that most controlled clinical studies used for registration focus on short-term or intermediate outcomes, such as those lasting a few weeks. Consequently, long-term effects related to effectiveness and recurrence management are not fully established in these reports.

Q: Is hair shedding or hair loss mentioned in the product information as a potential side effect of Себозол?

Yes, official product safety information includes hair loss (alopecia) and thinning hair among the adverse events that have been reported from post-marketing surveillance with the shampoo formulation.

Q: Can Себозол cause dryness or irritation of the scalp?

According to official safety information, application site reactions are among the adverse events that have been reported. These reactions include concerns such as dry skin, pruritus (itching), irritation, and a skin burning sensation.

Q: Is a burning sensation or tingling a recognized side effect of Себозол?

Yes, a skin burning sensation is listed among the adverse events that have been reported. Less frequently reported effects also include tingling sensations, which are referred to in medical terms as paresthesia, occurring at the application site.

Q: Does the use of Себозол affect the color or texture of treated hair?

Official reports confirm that both hair discoloration (changes to hair color) and abnormal hair texture have been reported as adverse events. This information comes from safety monitoring of the shampoo formulation.

Q: Is it possible for the treated area to become more sensitive to sunlight while using Себозол?

Regulatory warnings indicate that some topical formulations, such as the foam, carry a specific precaution. This precaution states that the product may make the skin more sensitive to light from the sun, a condition known as photosensitivity.

Q: Is it recommended to use a regular cosmetic shampoo on the days that Себозол is not used?

Official product information notes that when this medicated shampoo is used on the scalp, it is not necessary to follow up or alternate with a regular cosmetic shampoo after every application.

Q: What is the official guidance on using other topical hair products on the scalp while using Себозол?

Official patient counseling describes that products that may cause irritation are generally advised to be avoided. Examples of products include harsh soaps, hair coloring or perming chemicals, and products containing ingredients like alcohol or astringents.

Q: What steps should a user take if an application of Себозол is accidentally missed?

While specific instruction for a missed application is not detailed, patient counseling information includes a warning. This warning states that skipping applications or doses can increase the risk of the fungal infection becoming resistant to the medication.

Q: Is there information about using Себозол on body areas other than the scalp, such as the face or chest?

Yes, the cream formulation of the active ingredient is officially indicated for treating fungal conditions that affect the skin of the body, such as tinea corporis and tinea versicolor. These conditions frequently occur on areas like the face, chest, and trunk.

Q: What does official medical documentation say about using Себозол in children under 12 years of age?

Official medical documentation specifically states that the safety and effectiveness of the product have not been established in pediatric patients, defined as children younger than 12 years of age.

Q: What is the official regulatory guidance on using Себозол during pregnancy?

Regulatory guidance advises that the medicine should be used during pregnancy only if the potential benefit is judged to justify the potential risk to the fetus. This information means that the medicine's use requires careful consideration of the risks and benefits.

Q: Are there considerations mentioned in official documents for using Себозол while breastfeeding?

Official documentation notes that it is unknown if the drug is excreted into breast milk. Official advisories state that a decision involves considering whether to discontinue nursing or discontinue the drug, based on the medication’s importance to the patient.

Q: Is Себозол usage generally restricted for patients with certain pre-existing skin conditions?

Official documentation indicates that the product is contraindicated in individuals with a known allergy or hypersensitivity to any of the ingredients. Caution is also specifically advised for use on skin that is broken or inflamed.

Q: How is Себозол different from an everyday cosmetic anti-dandruff shampoo?

This product is classified as an antifungal medicine (Azole class) because it contains an active drug ingredient formulated to treat the underlying cause of infection. The product's classification indicates its purpose is to prevent the growth of fungi and yeasts, distinguishing it from standard cosmetic anti-dandruff shampoos.

Q: Is the active ingredient in Себозол a corticosteroid (steroid)?

No, the active ingredient is classified as an Azole antifungal and is not a corticosteroid (steroid). Official warnings detail a specific procedure for patients who are transitioning from long-term use of topical corticosteroids to this medicine.

Q: What is the difference in therapeutic purpose between an over-the-counter and prescription strength formulation?

Regulatory documentation indicates a difference in purpose based on concentration. The 1% over-the-counter strength is primarily indicated for dandruff control, while the 2% prescription strength is indicated for treating a wider range of fungal infections, including seborrheic dermatitis and various tinea infections.

Q: Why is Себозол sometimes compared to products containing Selenium sulfide in online discussions?

Official regulatory information confirms that both the active ingredient in this medicine and Selenium sulfide are classified as antifungal agents. Both ingredients are officially indicated for the treatment of scalp conditions, including dandruff, seborrheic dermatitis, and tinea versicolor.

Q: Can using a higher-than-recommended amount of Себозол at one time lead to increased skin irritation?

Patient counseling information states that using more of the medicine than directed will not make it work any faster. Furthermore, using more than the recommended amount or applying it more frequently may increase the risk of side effects.

Q: What specific first aid steps should be taken if Себозол accidentally gets into the eye?

Official patient warnings advise that if the medication accidentally comes into contact with the eyes, they should be rinsed thoroughly with water to minimize any potential irritation or adverse effect.

Q: Is the drug known by any other non-commercial or generic names in medical contexts?

The non-commercial or generic name of the active pharmaceutical ingredient is Ketoconazole. This generic name is used in medical and regulatory contexts worldwide.

Advertisements

How should Себозол be stored and disposed of?

The official regulatory guidelines for storing and disposing of this product's active ingredient, Ketoconazole topical, must be followed to ensure stability and safety.

Required Storage Conditions

Condition Requirement (Official Labeling)
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F), not exceeding 25 C.
Protection Protect from light and freezing. Keep away from excess heat and moisture.
Container Keep in the original container, tightly closed. Do not use past the expiration date on the label.

Disposal Instructions

Keep this medication out of the sight and reach of children. Unused or expired product should not be disposed of via wastewater or household waste unless specifically instructed. Consult a pharmacist or utilize a drug take-back program for appropriate disposal, adhering to all local and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Себозол found in:

A-Z Index: